Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2111363 Target Snapshot

Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) · PROTEIN COMPLEX · Homo sapiens

603Compounds
164Assays
6Approved Drugs
671.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O15379. Use UniProt O15379 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O15379 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) as ChEMBL target CHEMBL2111363, mapped to UniProt O15379. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2111363
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O15379
Histone deacetylase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) is the right protein anchor across sources, using UniProt O15379 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHistone deacetylase 3
UniProt AccessionO15379
Component TypeProtein
Sequence Length428 aa

Histone deacetylase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2), mapped to UniProt O15379. ChEMBL maps the protein component as Histone deacetylase 3. Sequence length is 428 aa.

Mapped IDO15379
Review nameHistone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

6
Approved
6
Phase III
4
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50643.0
KI27.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4444219 9.76 IC50 0.1726 Preclinical
CHEMBL99 9.59 Ki 0.26 Preclinical
CHEMBL5083249 9.42 IC50 0.38 Preclinical
CHEMBL5078985 9.37 IC50 0.43 Preclinical
CHEMBL5087431 9.26 IC50 0.55 Preclinical
CHEMBL4744689 9.18 IC50 0.66 Preclinical
CHEMBL3593247 9.15 IC50 0.7 Preclinical
CHEMBL5532146 9.14 IC50 0.72 Preclinical
CHEMBL3970532 9.0 IC50 1.0 Preclinical
CHEMBL5565699 8.97 IC50 1.08 Preclinical
Distribution

pChEMBL Value Distribution

37
5.0
70
5.5
89
6.0
82
6.5
101
7.0
76
7.5
41
8.0
33
8.5
9
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

GIVINOSTAT
CHEMBL1213492
Approved 2024
PANOBINOSTAT
CHEMBL483254
Approved 2015
ROMIDEPSIN
CHEMBL343448
Approved 2009
VORINOSTAT
CHEMBL98
Approved 2006
Assay Landscape

Assay Landscape

164
Total Assays
426
Tested Compounds
3
Assay Types
Binding — 152 assays, 426 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 75 263 6.9
protein complex format 63 141 6.9
assay format 14 22 6.9
ADME — 11 assays, 40 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 35 6.3
assay format 2 2 8.2
protein complex format 1 3 5.3
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine